Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack).

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack).

AIDS. 1991 Sep;5(9):1121-6. Unique Identifier : AIDSLINE MED/92029731
Chiasson MA; Stoneburner RL; Hildebrandt DS; Ewing WE; Telzak EE; Jaffe HW; New York City Department of Health, AIDS Research Unit, New York; 10013.

Abstract: A study of risk factors for HIV-1 infection was conducted at a sexually transmitted disease clinic in an area of New York City where the cumulative incidence of AIDS in adults through mid-1990 was 9.1 per 1000 of the population and where the use of illicit drugs, including smokable freebase cocaine (crack), is common. The overall seroprevalence among volunteers was 12% (369 out of 3084), with 80% of those who were seropositive reporting risk behavior associated with HIV-1 infection, including male-to-male sexual contact, intravenous drug use and heterosexual contact with an intravenous drug user. The seroprevalence in individuals denying these risks was 3.6% (50 out of 1389) and 4.2% (22 out of 522) in men and women, respectively. Among these individuals, the behaviors significantly associated with infection were use of crack and prostitution in women, and history of syphilis and crack use in men. These results suggest that in areas where the level of HIV-1 infection in heterosexual intravenous drug users is high and the use of crack is common, increased sexual activity (including the exchange of drugs or money for sex) may result in increased heterosexual transmission of HIV-1.

Keywords: *Crack Cocaine Female Human HIV Infections/COMPLICATIONS/EPIDEMIOLOGY/*TRANSMISSION HIV Seropositivity/*EPIDEMIOLOGY *HIV-1 Male New York City/EPIDEMIOLOGY Prevalence Prostitution/STATISTICS & NUMER DATA Risk Factors Sex Behavior/*STATISTICS & NUMER DATA Substance Abuse/*COMPLICATIONS/EPIDEMIOLOGY Substance Dependence Support, U.S. Gov't, P.H.S. Syphilis/COMPLICATIONS JOURNAL ARTICLE
920228
M9220833

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .